




# Projecten Programma Goed Gebruik Geneesmiddelen





*Dit overzicht bevat projecten uit de GGG open rondes, GGG registrerondes en de projecten opgenomen vanuit de programma's Doelmatigheidsonderzoek Farmacotherapie, Dure Geneesmiddelen, Priority Medicines Ouderen, Evidence based Medicine in Old Age, Priority Medicines Kinderen, Priority Medicines Antimicrobiële Resistentie. Voor details van een project zie [www.zonmw.nl](http://www.zonmw.nl) en het projectnummer in de zoekfunctie.*

## Sessie 1 Stimulering van drugrediscovery

Progr	Dossierrn	Titel	Projectleider/ instelling	Einddatum
DOF	170881007	Optimal treatment of rhinosinusitis-like symptoms: Double-blind placebo controlled randomized study with prednisolone versus usual care treatment	Dr. A.P.E. Sachs	1-9-2010

## Sessie 2 Onderzoeksdiseins: to RCT or not to RCT?

Progr	Dossierrn	Titel	Projectleider/ instelling	Einddatum
HTA	152002025	Novel modelling approaches to reconcile the paradigms of randomization and representativeness in (cost-) effectiveness analyses: The case of Rheumatoid Arthritis.	Dr. P.M.J. Welsing	1-4-2012
OR4	836041016	Analgesedation after cardiac surgery in infants: A "model-based" nation-wide randomized controlled trial.	Dr. M. van Dijk	1-2-2019

## Sessie 3 Focus op gendervraagstukken in geneesmiddelenonderzoek

Progr	Dossierrn	Titel	Projectleider/ instelling	Einddatum
Dof	94527003	A randomized controlled trial to assess the effectiveness of aspirin and anticoagulant treatment in women with unexplained recurrent miscarriage: ALIFE study (Anticoagulants for Living Fetuses)	Dr. S. Middeldorp	1-7-2009
Dof	170885601	Assessment of Perinatal Outcome after Sustained Tocolysis for Early Labour (APOSTEL II)	Dr. J.A.M. van der Post	1-5-2011
Dof	171102009	Remifentanyl patient-controlled analgesia (RPCA) vs epidural analgesia (EA) during labour.	Middeldorp	1-1-2015
OR2	836021004	Anti-TNF during pregnancy: safe for growth and development of the child?	Dr. C.J. van der Woude	1-4-2016
OR4	836041014	Insulin regime versus oral therapy for diabetes in pregnancy: the SUGAR-DIP trial	Drs. D.N. Voormolen - van Munster MD	1-12-2019
DOF	94501010	Prenatal fetal RhD bloodgroup typing to enhance efficiency of antenatal anti-D immunoprophylaxis in RhD negative pregnant women	Schoot, dr. C.E. van der	1-8-2005
Dof	171102020	The OPTIMIST trial: OPTIMalisation of cost effectiveness through Individualised FSH Stimulation dosages for IVF Treatment.	Broekmans	1-6-2016
OR1	836011012	Levothyroxine for euthyroid women with recurrent miscarriage and positive TPO antibodies: a randomized controlled trial (T4LIFE-trial)	M. Goddijn / AMC	1-4-2016
OR1	836011020	To treat or not to treat: depression during pregnancy and the impact on perinatal outcomes	N. Roeleveld / UMC St Radboud	1-4-2016
OR1	836011023	Superovulation in Intra uterine insemination: rFSH or Clomifene citrate?	M.H. Mochtar / AMC	1-6-2017



Goed Gebruik Geneesmiddelen

OR2	836021011	Tapering antidepressants in pregnancy: a pragmatic multicenter RCT to investigate risk and benefits for mother and child	Dr. M.P. Lambregtse - van den Berg	1-4-2018
OR3	836031002	"Why should I use my inhaler?" Development and testing of an adolescent adherence patient tool for asthma (ADAPT asthma -study)	Prof. dr. M.L. Bouvy PhD	1-4-2017
OR3	836031014	Antiplatelet therapy for patients undergoing transcatheter aortic valve implantation (TAVI)	Drs. V.J. Nijenhuis	1-11-2017
OR4	836041006	Low dose aspirin in the Prevention of Recurrent Spontaneous Preterm Labour – the APRIL study	Dr. M.A. de Boer	1-5-2018

## Sessie 4 Geneesmiddelen bij kinderen: kansen en afwegingen

Progr.	Dossiernr	Titel	Projectleider/instelling	Einddatum
PMK	90700304	Can genes predict kidney failure induced by tacrolimus therapy in pediatric transplant patients?	Dr. S.N. de Wildt	1-9-2015
PMK	90713494	Determination of new age-specific dosing guidelines for propofol in newborn infants using pharmacokinetic/pharmacodynamic (PK/PD) modeling as an innovative approach.	Dr. S.H.P. Simons	1-8-2017
PMK	92003549	Daily interruption of sedation + protocolized sedation (DSI+PS) vs. protocolized sedation (PS) in critically ill children.	Prof. dr. M. de Hoog	1-7-2017
PMK	92003555	Verschillende fenotypes van piepen op de kinderleeftijd: een genetische achtergrond	Prof. dr. D.S. Postma	1-1-2014
PMK	92003558	Steroid metabolism and cardiovascular risk factors in children with congenital adrenal hyperplasia	Dr. H.L. Claahsen-van der Grinten	1-1-2016
NKFK	113200951	Pediatric Dosing Module	T.M. van der Zanden/NKFK	1-6-2015
NKFK	113200952	Consumenten informatie over de toepassing van medicijnen bij kinderen	T.M. van der Zanden/NKFK	1-4-2016
PMK	113201002	Moderately early hydrocortisone for ventilated preterm infants at risk for bronchopulmonary dysplasia: A multicenter randomized placebo controlled trial	Dr. A.H.L.C. van Kaam/Academisch Medisch Centrum	25-8-2017
PMK	113201003	An efficacy, safety and pharmacokinetic study on the short-and long-term effects of Metformin in obese children/adolescents.	Dr. M.M.J. van der Vorst/St. Antonius Ziekenhuis	1-5-2017
PMK	113201004	A new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children	Dr. A. Warris/UMC St Radboud	1-9-2017
PMK	113201006	Effectiveness and safety of asthma controller therapy in the treatment of children with asthma	Dr. K.M.C. Verhamme/Erasmus MC	1-1-2016
PMK	113201007	Novel methods to assess and compare drug effects in pediatrics (EVIPED)	Prof. dr. J. van der Lei, Erasmus MC	1-1-2016
PMK	113202001	Infliximab top-down in pediatric Crohn's disease	Dr. L. de Ridder/Erasmus MC	1-3-2017
PMK	113202004	Towards a framework for development and implementation of pediatric oral liquids; amlodipine and lorazepam as proof of concept	Dr. L.M. Hanff/Erasmus MC	1-1-2017
PMK	113202005	Methylphenidate Treatment and the Developing Brain in Attention-Deficit/Hyperactivity Disorder	Dr. P.J. Hoekstra/Universitair Medisch Centrum Groningen	15-5-2016
PMK	113202007	Pediatric microdosing: elucidating age-related changes in oral absorption to guide dosing of new formulations	Dr. S.N. de Wildt/Erasmus MC	1-6-2016
PMK	113202009	The effect of intranasal insulin on development and behaviour of children with Phelan-McDermid syndrome.	Dr. C.M.A. van Ravenswaaij/Universitair Medisch Centrum Groningen	1-10-2015
Prio	113205007	New drugs for rare diseases: cost-effectiveness modelling in cryopyrin associated periodic syndromes (CAPS)	Prof. dr. A. Martini/IRCCS G. Gaslini	1-4-2015
Prio	113205008	Rare disease: use of clinical trial simulation for the choice and optimization of study design	Dr. P. Nony	1-9-2014



Goed Gebruik Geneesmiddelen

Prio	113205022	Paediatric Accelerator Mass Spectrometry Evaluation Research Study	Prof. dr. B.K. Park	1-2-2015
Prio	113205026	Validating non invasive imaging of the serotonergic- and dopaminergic system and adult neurogenesis with MRI; towards a better insight in the neurobiological mechanisms underlying psychiatric disorders in the paediatric population.	Dr. L. Reneman	1-2-2015
Prio	113205027	Acute lymphoblastic leukemia, children, minimal residual disease, flow cytometry	Dr. T.S. Szczepanski MD PhD	1-7-2014
OR2	836021022	Childhood Infections Limburg (CHILI):	Dr. J.W.L. Cals	1-5-2018
PMK	113202006	Exposure to the biological Anti-Thymocyte Globulin (ATG) and reconstitution of the immune system in children receiving allogeneic-Hematopoietic Stem Cell Transplantation (HSCT): Towards individualized dosing to improve survival	Dr. J.J. Boelens/Universitair Medisch Centrum Utrecht	1-4-2016
PMK	113202008	Neurogenic bladder in children: treatment with intravesical anticholinergics and use of feed-back tools.	Dr. D.J. Kok/ Erasmus MC	1-12-2017
PMK	113202010	Relevance of germline genetic variations for treatment response in pediatric osteosarcoma patients	Dr. D.M.W.M. te Loo/Radboud Universiteit Nijmegen	1-4-2015
EJ	113203006	Development and use of a standardised instrument for assessing children's competence to consent in drug trials: are legally established age limits valid?	Drs. I.M. Hein/De Bascule	1-9-2015
EJ	113203013	To store or not to store? A normative analysis of consent in pediatric biobanks.	Dr. A.L. Bredenoord/Universitair Medisch Centrum Utrecht	1-5-2014
EJ	113203014	Children involved in drug research: how to optimally protect them in practice?	Prof. dr. I.D. de Beaufort/Erasmus MC	1-3-2016
EJ	113203016	Tailored informed consent. Development of information material that appeals to children and delivers the message.	Prof. dr. J.M. van den Broek/Universiteit Leiden	1-6-2016
EJ	113203201	Ethical evaluation of dependent relationships in paediatric cancer drug research	Dr. R. van der Graaf/Universitair Medisch Centrum Utrecht	1-6-2015
EJ	113203202	Hearing the voices of the children (6-18 years); evidence-based information on burden and long-term emotional sequelae of medical research procedures in children	Prof. dr. J. Passchier PhD/Erasmus Medical Centrum	1-3-2016
EJ	113203203	Motivations of minors and their parents to consent or dissent to participation in paediatric clinical research	Dr. W.L.A. Pinxten/Erasmus MC	1-7-2016
Dof	171101005	The use of a Real-Time Medication Monitoring system (RTMM) for the improvement of adherence to inhalation corticosteroids in children with asthma	Dr. P.M.L.A. van den Bemt	1-3-2014
OR1	836011022	Population PKPD modelling to develop and implement guidelines to optimize safe and rational dosage of critical off-label drugs in critically ill premature infants	R. Groot / UMC St Radboud	13-6-2017
OR1	836021006	Reducing vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia by one-hour infusions instead of bolus injections	Dr. M.H. van den Berg	1-11-2017
OR1	836021012	Reducing vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia by one-hour infusions instead of bolus injections	Dr. R.J.M. Brüggemann	1-4-2017
Dof	837001008	Point-of-Care C-reactive protein to assist in primary care management of children with lower respiratory tract infection	Drs. B.D.L. Broekhuizen	1-12-2015
RR	836022004	Pharmachild-NL registry	Dhr. H.E. Vonkeman	1-1-2017
RR3	836042004	A patient register for botulinum toxin-A treatment in children with cerebral palsy	Prof. dr. J.G. Becher	1-6-2019




Goed Gebruik Geneesmiddelen

## Sessie 5 Kostbare geneesmiddelen (te) duur?

Prog.	Dossierrnr	Titel	Projectleider/ instelling	Einddatum
DG	152001001	Treatment of Fabry disease with the orphan drugs agalsidase alfa en agalsidase beta in the Netherlands: Health Technology Assessment related to Orphan Drug reimbursement policy.	Prof. dr. C.E.M. Hollak/ AMC	1-10-2011
DG	152001002	Cost-effectiveness and outcome of current treatment strategies in exudative age-related macular degeneration	Dr. J.S.A.G. Schouten / Maastricht Universitair Medisch Centrum+	16-12-2011
DG	152001003	Mucopolysaccharidosis type VI: Natural course, effects of enzyme therapy and health economic aspects. Long-term follow-up of untreated patients and patients receiving commercially available galsulfase (Naglazyme)	Prof. A.T. van der Ploeg / Sophia Kinderziekenhuis	1-10-2011
DG	152001004	Mucopolysaccharidosis type II: Natural course, effects of enzyme therapy and health economic aspects. Long-term follow-up of untreated patients and patients receiving commercially available Idursulfase (Elaprase)	Prof. A.T. van der Ploeg / Sophia Kinderziekenhuis	1-10-2011
DG	152001005	Effects and health economic aspects of enzyme therapy in children and adults with pompe disease. Long term follow-up of patients receiving commercially available alglucosidase alfa (Myozyme).	Prof. A.T. van der Ploeg / Sophia Kinderziekenhuis	1-10-2011
DG	152001006	An independent prospective randomised controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in 'high need' patients with moderate to severe chronic plaque type psoriasis	Dr. Ph.I. Spuls / AMC	1-10-2012
DG	152001007	Impact of new systemic treatments of patients with hematological malignancies in the Netherlands: population-based cohort studies of process and outcome as a basis for assessments of cost-effectiveness.	Prof. C.A. Uyl-de Groot / Erasmus Universiteit Rotterdam	1-10-2014
DG	152001008	More customized, cost-effective use of biologicals in treatment of rheumatoid arthritis.	Dr. A.C.A. Marijnissen / UMCU	1-1-2015
DG	152001009	Real world efficiency of Bevacizumab in Advanced Breast Cancer	Prof. dr. V.C.G. Tjan-Heijnen / MUMC	1-12-2012
DG	152001010	A multi-centre cost-effectiveness evaluation of a novel treatment option in the Netherlands: Photo Dynamic Therapy with temoporfine for the treatment of advanced incurable head and neck cancers, for whom prior conventional treatments have failed.	Prof. dr. I.B. Tan / NKI	1-2-2013
DG	152001011	National registry for the evaluation of treatment patterns, guideline adherence and use of expensive anti-fungals.	Prof. dr. B.J. Kullberg / UMC St Radboud	20-4-2012
DG	152001012	A cost-effectiveness and quality of life study on MAL-PDT in actinic keratoses and basal cell carcinoma	Dr. M.J.P. Gerritsen / UMC St Radboud	31-12-2013
DG	152001013	Basal cell carcinoma and actinic keratoses in the Netherlands: how often do they occur and who are at risk?	Dr. T.E.C. Nijsten / Erasmus MC	1-1-2013
DG	152001014	Impact of new approaches to pharmacological management of patients with renal cell carcinoma: a population-based study of process and outcomes in The Netherlands.	Prof. C.A. Uyl-de Groot / Erasmus Universiteit Rotterdam	1-4-2014
DG	152001015	SELDI-TOF analysis to predicted rituximab treatment outcome in rheumatoid arthritis patients.	Dr. M.J.H. Coenen / UMC St Radboud	1-6-2015
DG	152001016	Real world Efficiency of Trastuzumab in Early Breast Cancer	Prof. dr. V.C.G. Tjan-Heijnen / MUMC	1-5-2013
DG	152001017	Biomarkers for improving the cost-effectiveness and safety of pemetrexed	Prof. dr. B.H.C. Stricker / Erasmus MC	1-11-2015
DG	152001019	Impact of new approaches to the management of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (RM SCCHN: a population-based study of process and outcomes in The Netherlands.	Prof. C.A. Uyl-de Groot / Erasmus Universiteit	1-11-2013
DG	152001020	Treatment Sequencing in Multiple Myeloma: modeling the disease and evaluating cost-efficacy vs. cost-effectiveness	Prof. dr. P. Sonneveld / Erasmus MC	1-5-2015
DG	152001021	Eculizumab in patients with classic PNH: a cost effectivity study.	Dr. P. Muus / UMC St Radboud	1-4-2015



DG	152001023	Canakinumab in Cryopyrin-Associated Periodic Syndrome	Dr. A. Simon / UMC St Radboud	1-12-2016
DG	152041001	Potential optimisation of (Expediency) and Effectiveness of TNF-blockers	Dr. T.L.Th.A. Jansen / UMC St Radboud	1-11-2015
DG	152041002	Communicatieproject bij studie POEET	Drs. G.E.M.P. Willemsen - de Mey / Willemsen Consultancy	1-11-2015
DG	1520010011	Practical approach to improve the evaluation of orphan medicinal products: the case of Fabry disease	Prof. dr. C.E.M. Hollak	1-3-2015
DG	1520010051	Towards a more sensible development and meaningful implementation of orphan drugs	Prof. A.T. van der Ploeg	1-6-2016
RR	836007001	Haalbaarheidsstudie Dure Geneesmiddelen PatiëntenRegisters	Dr. L.E.A. Jansen-Landheer	1-7-2013
DOF	170885605	Comparative cost minimization study in treatment of superficial basal cell carcinoma: photodynamic therapy versus imiquimod versus fluorouracil, a randomized controlled trial	Dr. N. Kelleners-Smeets	1-8-2011
DOF	170885605	Comparative cost minimization study in treatment of superficial basal cell carcinoma: photodynamic therapy versus imiquimod versus fluorouracil, a randomized controlled trial	Dr. N. Kelleners-Smeets	1-8-2011
DOF	170995001	The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis	Prof. dr. P.L.C.M. van Riel	1-8-2015
DOF	1708856051	Implementatie resultaten: Comparative cost minimization study in treatment of superficial basal cell carcinoma: photodynamic therapy versus imiquimod versus fluorouracil, a randomized controlled trial (170885605)	Dr. N. Kelleners-Smeets	1-8-2015
DOF	170885606	Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration (COSD).	Dr. R.O. Schlingemann	1-12-2012
DOF	171202018	Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with retinal vein occlusions(The BRVO study)	Schlingemann	1-4-2016
DOF	171202019	Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema (The BRDME Study)	Schlingemann	1-4-2016
DG	152031001	Botuline Toxine Review	Dr. J. van Limbeek / Sint Maartenskliniek	31-12-2013
DG	152031002	Trastuzumab en taxanen in de behandeling van gemetastaseerd borstkanker	Prof. dr. V.C.G. Tjan-Heijnen / MUMC	31-12-2013
DG	152031003	OFFERTE. In het kader van het Programma Dure Geneesmiddelen voor uitvoering van review betreffende de ziekten van Crohn, Bechterew en artritis psoriatica met de focus op Infliximab (remicade) voor deze indicatie.	Prof. Dr. M.P. Peppelenbosch / Erasmus MC	31-12-2013
DG	152031004	Botulinetoxine behandeling bij focale dystonie	Prof. Dr. M.A.J. de Koning-Tijssen / AMC	31-12-2013
DG	152031005	Review of docetaxel, gemcitabine, paclitaxel and vinorelbine for the treatment of non-small cell lung cancer.	Prof. Dr. C.A. Uyl-de Groot / Erasmus Universiteit	31-12-2013
DG	152031006	Review of irinotecan, oxaliplatin, docetaxel and bevacizumab for the treatment of colorectal and gastric cancer.	Prof. Dr. C.A. Uyl-de Groot / Erasmus Universiteit	31-12-2013
DG	152031007	Review of bortezomib and other (expensive) drugs for the treatment of multiple myeloma.	Prof. Dr. C.A. Uyl-de Groot / Erasmus Universiteit	31-12-2013
DG	152031008	Offerte voor een review over het gebruik van Laronidase bij de ziekte Mucopolysaccharidose type	Prof. Dr. F.A. Wijburg / AMC	31-12-2013
DG	152031009	Review dure geneesmiddelen bij reumatoïde artritis	Mr. Drs. D.W.M. Jansen / Stichting Holding RCA/JBI	31-12-2013
DG	152031010	Review of docetaxel for the treatment of prostate cancer and gemcitabine for the treatment of pancreatic cancer.	Drs. H.M. Westgeest / VUMC	31-12-2013
DG	152031011	Review van overige vast tumoren	Dr. J.G. Hugtenburg / VUMC	31-12-2013
DG	152031012	Review plaatsbepaling immunoglobulines op beleidsregel dure geneesmiddelen	Dr. A. Simon / Radboudumc	31-12-2013



## Sessie 6 Medicatie overdracht staat centraal

Progr.	Dossiernr	Titel	Projectleider/ instelling	Einddatum
STIP1	836044001	Communicatieadvies op maat voor apothekemedewerkers in de poliklinische apotheek: ontwikkeling en implementatie van een online feedback instrument (COM-MA)	Dr. ir. L. van Dijk	1-11-2016
STIP1	836044002	Veilige principes verder in praktijk	A. Bolscher	1-11-2016

## Sessie 7 Cel- en gentherapie als geneesmiddel

Progr.	Dossiernr	Titel	Projectleider/ instelling	Einddatum
Dof	94507606	Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system.	Prof. dr. B. Franke	1-3-2012
DOF	171102022	Cost-effectiveness of CYP2C19 genotype guided treatment with antiplatelet drugs in patients with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention with stent implantation: optimization of treatment	Deneer	1-9-2017
DOF	171102024	Personalized prophylaxis of venous thrombosis based on genetic and other risk factors in a population at risk.	Cannegieter	1-10-2015
OR4	836041013	TailoRing anti-androgEn therapy For metastatic castration resistant prostate cancer based on early tumor response markers In combiNation with drug Exposure measurement (REFINE-project)	Dr. N.P. van Erp	1-10-2018

## Sessie 8 Innovatieve studies bij ouderen

Progr.	Dossiernr	Titel	Projectleider/ instelling	Einddatum
DOF	94502009	PINE: Prevention by epidural Injection of postherpetic Neuralgia in the Elderly	Verheij, Prof.dr. Th.J.M.	1-12-2004
PMO	113101001	SCREEN: Supporting Clinical Rules in the Evaluation of Elderly patients with Neuropsychiatric disorders	Dr. P.H.M. van der Kuy/Orbis Medisch Centrum	1-4-2016
PMO	113101001	SCREEN: Supporting Clinical Rules in the Evaluation of Elderly patients with Neuropsychiatric disorders	Dr. P.H.M. van der Kuy/Orbis Medisch Centrum	1-2-2015
PMO	113101002	Utilisation, effectiveness in daily practice, and adverse effects of antidepressants in ambulatory elderly.	Dr. L.E. Visser/Erasmus MC	1-4-2015
PMO	113101003	Effects of temporary discontinuation of antihypertensive treatment in older patients with cognitive impairment	Prof. dr. R.C. van der Mast/Leids Universitair Medisch Centrum	1-3-2015
PMO	113101004	Towards optimal vitamin D treatment to decrease fall and fracture risk, improve the metabolic profile and decrease the risk for depression.	Prof. dr. P. Lips/VU medisch centrum	1-4-2015
PMO	113101005	Quality of prescription of psychotropic drugs in nursing home patients with dementia: need for optimization	Dr. D.L. Gerritsen/Radboud Universiteit Nijmegen	1-7-2015
PMO	113101006	Association between common genetic variation and drug-related valincidents in older persons	Dr. N. van der Velde/Erasmus MC	1-1-2016
PMO	113101007	Towards safe and effective use of medication: prediction scores for major fracture risk assessment in the general elderly population and in elderly patients with rheumatoid arthritis.	Dr. F. de Vries/Erasmus MC	1-1-2016
PMO	113102002	Effects and Cost-Effectiveness of Pharmacogenetic Screening among Elderly Starters with Antidepressants: A Pragmatic Randomized Controlled Trial.	Prof. dr. B. Wilffert/Rijksuniversiteit Groningen	1-8-2016
PMO	113102003	The effectiveness of optimizing pharmacological treatment in patients with geriatric problems in general practice	Prof. dr. F.G. Schellevis/NIVEL	1-5-2016




Goed Gebruik Geneesmiddelen

PMO	113102004	Population-based use and effectiveness of 5-fluoruracil, oxaliplatin, and/or capecitabine among elderly patients with stage III colon cancer	Dr. V.E.P.P. Lemmens/Integraal Kankercentrum Nederland	1-5-2016
PMO	113102005	Risk factors for ventricular arrhythmia and sudden cardiac death as an adverse reaction of commonly used drugs in the elderly.	Dr. M. Eijgelsheim MD/Erasmus MC	1-5-2016
PMO	113102006	Towards optimal treatment in elderly type 2 diabetes patients.	Dr. L.M. 't Hart/Leiden University Medical Center	1-11-2016
EPHOR	113104001	Expertisecentrum PHarmacotherapie bij OudeRen (EPHOR)	Dr. P.A.F. Jansen	1-1-2014
EMO	627002001	Towards innovation of clinical trials in old age using modern technology and alternative methodology	Dr. S.P. Mooijaart / Institute for Evidence-Based Medicine in Old Age (IEMO)	1-10-2016
EMO	627003001	Evidence based Medicine in Old Age	Dr. S.P. Mooijaart MD PhD	1-1-2017
Dof	170885607	[Cost]effectiveness of medication withdrawal in older fallers: a randomized controlled trial at the Accident and Emergency Department.	Dr. T.J.M. van der Cammen	1-12-2012
Dof	171103007	Pharmacotherapy counselling groups using quality circles: a cost-effective strategy to improve guideline adherence in nursing homes?	Drs. P.J.E.M. Geels	1-5-2015
OR1	836011016	Ticagrelor and prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome and a high bleeding risk: optimization of antiplatelet treatment in high-risk elderly	V.H.M. Deneer / St. Antonius Ziekenhuis	1-5-2016
OR1	836011019	Discontinuing inappropriate medication in nursing home residents (DIM-NHR study)	K. Taxis / RUG	1-6-2015
OR2	836021014	Pregnancy immunoglobulin for the prevention of congenital cytomegalovirus infection (PICCOLO)	Dr. E. Pajkrt	15-4-2018
STIP1	836044003	Het transmurale fractuurpreventieprogramma: implementatie van een transmuraal zorgprogramma ter preventie van fracturen bij patiënten met een eerdere fractuur na het vijftigste levensjaar.	Dr. P.J.M. Elders	1-6-2017

## Sessie 9 Samen beslissen in de spreekkamer

Progr.	Dossierrn	Titel	Projectleider/ instelling	Einddatum
OR3	836031001	The effect of oral ondansetron on referral rate in children aged 6 months to 6 years, attending in primary care out of hours service with acute gastro-enteritis and vomiting	Dr. Y. Lisman-van Leeuwen	1-1-2019
STIP1	836044004	Implementatie van therapeutic drug monitoring middels dried blood spots in de dagelijkse praktijk.	Prof. dr. D.J. Touw	1-11-2016
STIP1	836044005	Optimaliseren van goed gebruik van geneesmiddelen door dialysepatiënten: het ontwikkelen en implementeren van doseringsadviezen én een patiëntbegeleidingsprogramma	Drs. M. Journée-Gilissen	1-9-2017
STIP1	836044010	Samen werken aan veilig medicijngebruik onder laaggeletterde patiënten in de eerstelijns	Dr. K. Hosper	1-12-2016
RR	836022006	Dutch Registry of Patients with Hemophilia and associated Disorders	Dr. F.J.M. van der Meer	1-12-2017



## Sessie 10 Nieuwe initiatieven in de strijd tegen antibioticaresistentie

Pogr.	Dossierrnr	Titel	Projectleider/ instelling	Einddatum
DOF	94517303	Implementation of a multiple intervention aimed at optimising prescription of antibiotics for respiratory tract infections, embedded within the new practice accreditation of the Dutch College of General Practitioners; a randomised controlled trial	Dr. M.M. Kuyvenhoven	1-6-2012
Dof	170992502	Comparison of otological antibiotic-steroid drops or oral antibiotics versus watchful waiting in children with acute tympanostomy tube otorrhea	Prof. dr. A.G.M. Schilder	1-3-2013
DOF	170993002	Cost-Effectiveness of two different strategies to improve the quality of antibiotic use in patients with urinary tract infections (UTIs) in the hospital	Dr. S.E. Geerlings	1-6-2013
DOF	171002301	Is antibiotic treatment associated with reduced risk of a subsequent exacerbation and mortality in chronic obstructive lung disease? A randomized clinical trial.	Prins	1-10-2015
DOF	171002302	Antibiotic prophylaxis with ceftriaxone to prevent infections in patients with stroke: a randomized controlled trial	Nederkoorn	1-7-2015
DOF	171103003	Analysis and elimination of barriers to the implementation of an early switch of intravenous to oral antibiotic therapy for the treatment of severe community-acquired pneumonia in the Netherlands	Dr. J.J. Oosterheert	1-11-2011
DOof	171202002	Cost-effectiveness of antibiotic treatment of community-acquired pneumonia (CAP): a cluster-randomized, multi-center, cross-over trial of 3 recommended treatment strategies.	Bonten	1-9-2014
AMR	205100003	Development of generic quality indicators for the optimisation of antibiotic use in the hospital	Dr. S.E. Geerlings / AMC	1-6-2014
AMR	205100004	Reduce antibiotics use by wait-and-see prescription	S. van Nuland / IVM	26-3-2014
AMR	205100007	Bacterial DNA Load (BDL) detection as a rapid diagnostic and monitoring tool for optimal antibiotic treatment in bacterial endocarditis	Prof. dr. P.H.M. Savelkoul / VUMC	1-11-2014
AMR	205100011	Improving rational prescribing of antibiotics in Long Term Care facilities (IMPACT)	Prof. dr. C.M.P.M. Hertogh / VUMC	1-12-2014
AMR	205100015	Comprehensive Analysis of the Effect of Oropharyngeal and Intestinal Decontamination on Antibiotic Resistance - Towards Decision Criteria for a Risk-Benefit Analysis of Prophylactic Antibiotic Therapies	Dr. ir. W. van Schaik / UMC Utrecht	1-12-2014
AMR	205200002	Efflux pump inhibition or cell membrane destabilization in Mycobacterium tuberculosis to enhance the activity of TB drugs and prevent drug resistance	Dr. R.E. Aarnoutse / Radboudumc	1-7-2016
AMR	205200006	Carbapenem-resistance selection and characterization of Enterobacteriaceae carrying plasmid-encoded AmpC beta-lactamases	Dr. W.H.F. Goessens / Erasmus MC	1-6-2014
AMR	205200008	Improving antibiotic use for children with acute respiratory tract infections	Prof. dr. Th.J.M. Verheij / UMC Utrecht	19-12-2015
OR1	836011024	The DANCE study (Duration of ANTibiotic therapy for CEllulitis): Is 6 days of antibiotics equal to standard 12 days of treatment for cellulitis? A randomized clinical trial.	W.J. Wiersinga / AMC	1-4-2017
OR1	836011028	New use of aminoglycosides: Prevention of recurrent urinary tract infections by multi-drug resistant bacteria, by intravesical administration of antibiotics.	J.T. van Dissel / LUMC	1-5-2015
OR2	836021001	Optimal antibiotic use: an "antibiotic checklist" for all bacterial infections in the hospital	Dr. S.E. Geerlings	1-6-2017
OR3	836031005	Antibiotic prophylaxis to prevent wound infections following implant removal after foot, ankle and lower leg fractures.	Drs. T. Schepers	1-5-2017
DOF	94504010	RCT of point of care C-reactive protein test and enhanced communication skills for managing acute cough due to lower respiratory tract infection in general practice: cost effectiveness and effect on diagnostic testing, antibiotic prescribing and recovery.	Prof. G-J Dinant	1-2-2008
DOF	171002303	A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLA trial).	Boermeester	1-6-2013



Goed Gebruik Geneesmiddelen

DOof	171101011	Cost efficacy of prophylactic treatment with antibiotics during concomitant chemoradiotherapy in patients with locally advanced head and neck cancer to prevent aspiration pneumonia.	Dr. C.M.L. van Herpen	1-1-2016
OR2	836021008	Goal oriented therapy with intravenous colistin to optimally treat infections with multidrug-resistant Gram-negative bacteria (COLIGO study)	Dr. H.J.M. van Kan	31-12-2015
OR2	836021021	A computer-assisted decision support model used for antibiotic stewardship	Prof. dr. A. Verbon	1-4-2018
OR4	836041001	STRAP -Study to Reduce Antibiotic prescription in childhood Pneumonia: implementation of a validated decision rule to target antibiotic prescription in children with suspected community acquired pneumonia	Dr. R. Oostenbrink	1-4-2018
OR4	836041004	Individualized dosing of AMInoglycosides and Glycopeptide antibiotics in (morbidly) Obese patients (AMIGO): clinical studies and implementation in clinical practice.	Prof. dr. C.A.J. Knibbe	1-4-2019


## Sessie 11 Personalised Medicine: visie en ontwikkelingen

Progr.	Dossierrnr	Titel	Projectleider/ instelling	Einddatum
OR1	836011009	Treatment of patients with Fabry disease with agalsidase alfa and agalsidase beta: phenotypic diversity necessitates the development of individualized treatment guidelines.	C.E.M. Hollak / AMC	1-2-2016
OR1	836021019	The Netherlands Breast Cancer Project (NBCP): Towards personalized medicine by using the nationwide population-based breast cancer registry (1989-2011) coupled with biobanking.	Prof. dr. S.C. Linn	1-12-2016
OR1	836031008	Optimization of Eculizumab/Soliris® treatment in patients with atypical hemolytic uremic syndrome by means of individually-tailored, personalized therapy.	Dr. N.C.A.J. van de Kar	1-3-2017
RR	836001005	Het ontwikkelen van een nationale database voor het gebruik van biologicals en andere systemische medicatie bij patiënten met matig-ernstige tot ernstige psoriasis.	Dr. J.J.E. van Everdingen / Nederlandse Vereniging voor Dermatologie en Venereologie	1-6-2013
RR	836002002	Implementatie medicamenteuze behandeling van gemetastaseerd melanoom in Nederland	Dr. ir. J.J.M. van der Hoeven / MCA	31-4-2014
DOof	94501015	Shorter treatment duration of endocarditis based on C-reactive protein values	prof dr. P. Speelman,	1-1-2004
DOf	94502029	Arthroscopy to predict the response to TNF-a blockade	Prof. dr. P.P. Tak,	1-7-2005
DOf	94527015	Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma (MONOSA-Study)	Dr. E.H.D. Bel	1-3-2009
OR1	836011001	Shortcomings in guidelines: parameters for initiating anti-TNF in inflammatory bowel disease patients: the development of an anti-TNF decision model.	C.J. van der Woude / Erasmus MC	1-4-2015
OR1	836021007	Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients.	Dr. P. Denig	1-10-2016
OR4	836041005	Introduction of a biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis	Prof. dr. N.M. Wulffraat Arts	1-1-2019
DOf	1708856019	The value of information in the evaluation of diagnostic and screening tests	Dr. B.C. Opmeer	1-1-2011



## Sessie 12 GGZ in de schijnwerpers

Progr.	Dossierrnr	Titel	Projectleider/ instelling	Einddatum
DOF	94501001	Quality of life in first onset schizophrenia	Prof. dr. D. Wiersma / Dr. L. Wunderink	1-8-2005
DOF	170885608	Clozapine vs olanzapine as second generation antipsychotic medication (SGA) in the six months treatment of patients with schizophrenia and related disorders and co-morbid substance use disorders (SUD): a multi-centre double blind randomized trial	Prof. dr. L. de Haan	1-9-2012
OR1	836011004	Personal Antipsychotic Choice Index	L. de Haan / AMC	1-6-2015
OR1	836011018	Concordance in pharmacotherapy in patients with epilepsy	S.M.A.A. Evers / MUMC	1-6-2016
OR2	836021015	Less may be more; reducing and rationalizing polypharmacy in schizophrenia	Drs. A. Wunderink	1-10-2016
OR3	836031013	Oral ketamine for Treatment Resistant Depression; new indication for an 'old' anesthetic and analgesic drug	Prof. dr. R.A. Schoevers	1-2-2019
OR3	836031016	Reducing aggression among chronic psychiatric inpatients through supplementation of multivitamins, minerals and n-3 fatty acids	Drs. A. Schat	1-3-2019
OR4	836041015	Repositioning bumetanide for the treatment of Autism Spectrum Disorder	Dr. H. Bruining Arts	1-4-2019
DOF	170992906	INAPPROPRIATE LONG TERM ANTIDEPRESSANT PRESCRIPTION IN GENERAL PRACTICE; cost effectiveness of discontinuation of antidepressant prescribing and patient tailored treatment advice.	/Prof. dr. R.C. Oude Voshaar	1-5-2013
DOF	171001007	D-cycloserine enhancement of exposure and response prevention (ERP) therapy in OCD and panic disorder with agoraphobia: a randomized controlled trial	Dr. D.C. Cath	1-6-2014
DOF	171001008	The efficacy of a CBT relapse prevention program for remitted anxiety disorder patients who discontinue antidepressant medication.	Prof. dr. A.J.L.M. Balkom	1-12-2012
OR1	836011010	Cost-effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: a randomized controlled trial.	C.L. Mulder / Erasmus MC	1-11-2017
OR2	836021003	Clonidine als veelbelovende aanvulling op de behandeling van refractaire symptomen van schizofrenie	Dr. B. Oranje	31-12-2017
OR2	836021020	Off label use of antipsychotics in vulnerable groups: survey of prescription policy and controlled discontinuation studies in children and adolescents and in individuals with intellectual disability with disruptive behavior problems	Dr. P.J. Hoekstra	1-4-2018
OR4	836041008	Augmentation with raloxifene: towards a better outcome for patients with schizophrenia spectrum disorders	Dr. S.M. Heringa	10-1-2019
STIP1	836044007	Ondersteuning van de POH GGZ bij aanpak chronisch gebruik benzodiazepinen via motiverende gespreksvoering en gepersonifieerde patiëntenvoorlichting	Dr. G. Rodenburg	1-12-2016
RR	836022003	Adding in- and outpatient pharmacotherapeutic treatment information to a psychiatric case registry	Dr. E.R. Heerdink	1-5-2016
OR1	836011014	How appropriate is the increasing long term use of methylphenidate? A practice audit and placebo controlled discontinuation trial.	P.J. Hoekstra / Accare Groningen	1-5-2017



## Overige projecten

Progr.	Dossierrnr	Titel	Projectleider/ instelling	Einddatum
EJ	113105002	Developing medicines for vulnerable groups A legal and ethical study on adequate consent procedures in relation to gaining or losing competence to consent to participation in research	Dr. mr. M.C. Ploem	1-10-2015
EJ	113105003	ETHICally sound inclusion of PREGnant women in MEDical research - PREGMETHICs study	Dr. R. van der Graaf	1-6-2016
EJ	113105004	The value of reducing uncertainty: merging ethics and economics	Prof. dr. G.J. van der Wilt	1-02-2016
HTA	152002012	Feasibility of cancer registries as a Health Technology Assessment tool in pharmacotherapy	Prof. dr. J.W.W. Coebergh / Erasmus MC	1-5-2011
RR	836001003	Infrastructuur voor ziekenhuis-georiënteerd geneesmiddelen uitkomsten onderzoek	Drs. M.M. Tjoeng / St. Antonius Ziekenhuis	1-1-2013
RR	836001004	Verkenning haalbaarheid Basisstructuur Innovatief Diabetes Onderzoek (BIDON) - Een landelijke anapak van gegevensverzameling rond (nieuwe vormen van behandeling van) diabetes -	Drs. M.J. de Groot / Nederlandse Diabetes Federatie	1-2-2013
RR	836012001	The Pregnancy Drug Register: development and implementation	Dr. A.C. Kant / Lareb	15-8-2015
RR	836012002	Dutch south west Early Psoriatic Arthritis Registry (DEPAR-R)	Dr. I. Tchvetverikov / Albert Schweizer Ziekenhuis	1-12-2015
RR	836022002	A national registry for Systemic Lupus Erythematosus (SLE) in the Netherlands	Dr. A.E. Voskuyl	1-4-2016
RR	836022005	Development of a registry for improving rational use of pharmacotherapy for chronic hepatitis B and C patients	Prof. dr. H.W. Reesink	18-8-2015
RR3	836042001	Registry for spondyloarthritis in the Netherlands - SpA-Net	Dr. A.M. van Tubergen	1-3-2018
RR3	836042002	IB-DREAM: Registry for inflammatory bowel diseases in The Netherlands	Dr. F. Hoentjen	1-5-2018
RR3	836042003	Registry of Adult Patients with Severe asthma for Optimal Disease management(RAPSODI)	Prof. dr. E.H.D. Bel	1-5-2018
DOF	94503052	Management of patients with dyspepsia	Laheij, Dr. R.J.F.	1-8-2006
DOF	94507602	Triptan overuse in migraine in primary care, a proactive approach.	Dr. A. Knuistingh Neven	1-8-2010
DOF	94511016	Evaluating Chemotherapy Response with FDG PET in Metastatic Breast Cancer	van Rijk, Dr. P.P.	1-5-2003
DOF	170881004	Rivastigmine for delirium in Intensive Care patients, a double-blind, randomised placebo-controlled add-on trial	Dr. A.J.C. Slooter	1-4-2011
DOF	170885602	The DEXamethasone for Cardiac Surgery (DECS) trial: A large but simple trial to quantify the cost-effectiveness of dexamethasone in patients undergoing cardiac surgery.	Dr. D van Dijk	1-9-2011
DOF	170885603	A randomised controlled trial in the palliative setting regarding off-label medication: investigating the efficiency of amitriptyline versus pregabalin from a societal perspective	Dr. Y.M.P. Engels	1-9-2012
DOF	170885604	ACCURATE: Asthma Control Cost-Utility RANdomized Trial Evaluation Goals of asthma treatment: how high should we go?	Dr. J.K. Sont	1-5-2012



Goed Gebruik Geneesmiddelen

DOF	170995002	Cost-effectiveness of subcutaneous immunotherapy in allergic rhinitis	Dr. R. Gerth van Wijk	1-5-2013
DOF	170995004	A randomized, double-blind, controlled withdrawal trial in Crohn's Disease Patients in long-term remission on mesalazine.	Dr. B. Oldenburg	1-2-2012
DOF	170995005	Pharmacologic optimization of voriconazole - a prospective clustered group-randomized cross-over trial of therapeutic drug monitoring	Dr. J.G.W. Kosterink	1-1-2017
DOF	171002304	Efficiency, efficacy and costs of guideline-based therapeutic strategies for patients with proven or possible persistent Lyme disease.	Kullberg	1-1-2015
DOF	171101004	Intensive pharmacovigilance of high-risk patients on hospital surgical wards	Drs. J.M. Bos	1-8-2013
DOF	171102001	Treatment with low molecular weight heparin after knee arthroscopy and lower leg immobilisation	Cannegieter	1-10-2015
DOF	171102017	Development and validation of a delivery outcome measure	Akker	1-4-2014
DOF	171201003	Reducing the incidence of painful crisis in patients with sickle cell disease	Dr. B.J. Biemond	1-4-2016
OR1	836011005	Nifedipine versus Atosiban in the treatment of threatened preterm labour: APOSTEL III	M.A. Oudijk / UMCU	1-1-2016
OR1	836011006	HPV vaccination after treatment of anal intraepithelial neoplasia	J.M. Prins / AMC	1-4-2017
OR1	836011007	Long term effectiveness of biological use for rheumatoid arthritis in daily clinical practice: analyses on the DREAM registry	W. Kievit / UMC St. Radboud	1-4-2015
OR1	836011008	Characterization of the influence of (morbid) obesity on CYP3A4-mediated clearance using midazolam as a model drug: towards evidence-based dosing in obesity.	C.A.J. Knibbe / St. Antonius Ziekenhuis	1-9-2015
OR1	836011011	"OPTI-CLOT": Peri-Operative Pharmacokinetic-guided dosing of CLOTting factor in Hemophilia	M.H. Cnossen / Erasmus MC	1-2-2018
OR1	836011013	Low-dose dexamethasone in newly diagnosed pulmonary sarcoidosis: a low-cost treatment with favorable outcome	I.H.E. Korenromp / St. Antonius Ziekenhuis	1-6-2015
OR1	836011015	Paracetamol or NSAIDs in acute musculoskeletal syndromes	M.L. Ridderikhof / AMC	1-6-2016
OR1	836011017	Patient reported outcomes in the CAstration-resistant Prostate cancer Registry (CAPRI)	Prof. C.A. Uyl-de Groot	1-1-2018
OR1	836011021	Prevention of thromboembolic complications to optimize treatment for acute lymphoblastic leukemia	B.J. Biemond / AMC	2-5-2016
OR1	836011025	Optimizing pharmacotherapy by redefining the role of the pharmacist: integration of the nondispensing clinical pharmacist in the primary care team.	A.J. Leendertse / UMCU	15-6-2016
OR	836011026	Randomized Double-Blind Placebo-Controlled trial of Intradiscal Methylene Blue Injection for Chronic Discogenic Low Back Pain	M. Kleef / MUMC	15-1-2017
OR1	836011030	Early discontinuation vs extended treatment with imipenem for unexplained fever during neutropenia in hematology patients receiving antimicrobial prophylaxis: a randomised non-inferiority trial.	Dr. M.A. van Agtmael	1-4-2017
TD	836013001	NOAC pilot 1	Dr. M.V. Huisman MD PhD	1-6-2014
OR1	836021002	Step-down versus step-up analgesics in patients with (sub)acute sciatica in primary care	Dr. P.A.J. Luijsterburg	22-4-2017
OR2	836021005	Optimizing DMARD therapy for primary Sjogren's syndrome	Dr. J.A.G. van Roon	1-3-2017



Goed Gebruik Geneesmiddelen

OR2	836021009	Rituximab in life threatening therapy resistant progressive interstitial pneumonitis	Drs. H. Adams MD	22-7-2016
OR2	836021010	Overtreatment with intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy	Prof. dr. I.N. van Schaik	1-4-2017
OR2	836021016	Effectiveness of routine nebulisation of mucolytic agents and bronchodilating drugs in intubated and ventilated intensive care unit patients.	Dr. F. Paulus	1-4-2016
OR2	836021017	Prothrombin Complex Concentrate (PCC) for the immediate reversal of the anticoagulant effects of new oral anticoagulants in emergency situations	Prof. dr. S. Middeldorp	1-8-2016
OR2	836021018	Co-administration of proton pump inhibitors in patients prescribed long-term low-dose aspirin: benefit, harm and cost-effectiveness	Dr. A. Tran Duy	1-4-2017
OR2	836021023	The Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine growth Restriction) Trial	Dr. J.W. Ganzevoort	15-11-2018
OR3	836031003	Development and testing of an adolescent adherence patient tool for asthma (ADAPT asthma -study)	Dr. M.J.H.A. Kruip	1-7-2018
OR3	836031004	Prevention of ICU delirium and delirium-related outcome with haloperidol; a multicentre randomized controlled trial	Dr. M. van den Boogaard	1-1-2017
OR3	836031006	Tailored intervention focused on self-management and acceptance to improve adherence of patients with haemophilia using prophylactic home treatment.	Drs. Lh. Schrijvers	1-11-2018
OR3	836031007	Hyperoxia: too much of a good thing?	Prof. dr. Y.M. Smulders	1-11-2018
OR3	836031009	Duloxetine for chronic osteoarthritis pain; an important alternative	Dr. D. Schiphof	1-1-2018
OR3	836031010	Effects of food on the pharmacokinetics of nilotinib in chronic myeloid leukemia: assessment of a tailored dose reduction (NiFo-study)	Dr. J.G. Hugtenburg	1-6-2016
OR3	836031011	"Topical ingenol mebutate versus photodynamic therapy versus topical 5-fluorouracil versus topical Imiquimod in treatment of actinic keratosis: a multi-center randomized fase III efficacy and cost-effectiveness study".	Dr. K. Mosterd	1-12-2017
OR4	836041003	Tight control dose-reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.	Dr. E.M.G.J. de Jong	1-6-2016
OR4	836041007	Zoledronate as disease modifier in osteoarthritis	Dr. W.H. Noort-van der Laan	1-1-2020
OR4	836041009	Efficacy of paracetamol, NSAIDs and advice for patients with acute low back pain: a placebo controlled trial (PACE-plus)	Prof. dr. B.W. Koes	10-1-2019
OR4	836041010	Are ursodeoxycholic acid, mesalazine, thiopurines, and non-steroidals efficacious and cost-effective in primary sclerosing cholangitis? A nationwide study.	Dr. C.Y. Ponsioen	1-11-2018
OR4	836041012	The effect of tocolysis with nifedipine or atosiban on infant development (APOSTEL III follow-up)	Dr. M.A. Oudijk	1-1-2018
OR4	836041017	Increased cancer incidence in patients with type 2 diabetes using sulphonylureas?	Dr. G.W.D. Landman Arts	1-5-2019
STIP1	836044006	Lithium, alleen verantwoord met zorgvuldige controle.	Dr. R. Hoekstra	1-7-2017
STIP1	836044008	Transmurale samenwerking bij ziekenhuisontslag om de continuïteit van zorg te optimaliseren voor de patiënt	Dr. F. Karapinar	1-12-2016
STIP1	836044009	Ontwikkeling en implementatie van doseeradviezen voor geneesmiddelen bij patiënten met levercirrose	Dr. S.D. Borgsteede	1-12-2016



Goed Gebruik Geneesmiddelen

HTA	152002001	Potential and limitations of a Bayesian approach to the analysis and synthesis of evidence from multiple, heterogeneous sources. An inquiry into its usefulness in supporting policy decisions on drugs.	Prof. Dr. G.J. van der Wilt	01-12-2011
HTA	1520020011	Implementatie van Bayesiaanse analyses ter ondersteuning van vergoedingsbeslissingen over geneesmiddelen	Prof. Dr. G.J. van der Wilt	01-01-2015
HTA	152002002	UPDATING PARAMETERS OF DECISION-ANALYTIC COST EFFECTIVENESS MODELS: A SYSTEMATIC COMPARISON OF METHODS.	Prof. Dr. M.P.M.H. Rutten-van Mölken	15-02-2011
HTA	152002003	Further exploration of the appropriateness of the well-being valuation method for monetary valuation of informal care: what is measured?	Dr. M.E. van den Akker-van Marle	15-12-2011
HTA	152002004	Treatment of severe hemophilia: Optimal data-usage for optimal treatment strategies	Prof. Dr. B.A. van Hout	01-10-2011
HTA	152002005	Prioritizing and designing outcomes research: the role of value of information analysis	Dr. M.J. Al	01-05-2011
HTA	152002006	Bayesian Value of Information and Indirect Comparison Methodologies Applied to Dutch Expensive In-hospital Drugs: optimizing information gathering and synthesis illustrated for anti-fungal drugs	Prof. Dr. M.J. Postma	01-07-2011
HTA	152002007	A framework for real world economic evaluation of pharmaceuticals	Dr. J.P.C. Grutters	01-12-2009
HTA	1520020071	VIMP Value of Information	Dr. M.A. Joore	30-06-2015
HTA	1520020072	Onderzoekskosten onderzocht. Een kostenstudie naar de kosten van door ZONMW programma's gesubsidieerd onderzoek	Dr. T.L. Feenstra	15-02-2016
HTA	152002008	Discounting Health Effects; further analysis of its rationale and the theoretical & empirical implications	Prof. Dr. M.J. Postma	01-09-2011
HTA	152002009	The inclusion of informal care in health economic evaluations: developing a standardised, modular instrument and user manual including the CarerQol	Prof. Dr. W.B.F. Brouwer	01-06-2011
HTA	152002010	Correcting health state valuations derived with TTO for discounting	Prof. Dr. W.B.F. Brouwer	01-06-2011
HTA	152002011	Equity weights for QALYs	Prof. Dr. W.B.F. Brouwer	01-06-2011
HTA	152002012	Feasibility of cancer registries as a Health Technology Assessment tool in pharmacotherapy	Prof. Dr. V.E.P.P. Lemmens	01-05-2011
HTA	152002013	Quality of life in expensive drugs: deriving preferences in absence of generic health state valuations	Dr. E.A. Stolk	01-06-2011
HTA	152002014	Advanced value of information methods to health technology assessment of expensive medicine and orphan drugs	Dr. Ir. T. Hoomans	01-04-2011
HTA	152002015	From disease specific health status to generic utility. Methods to improve piggy-back utility analysis in controlled clinical trials	Prof. Dr. C.A. Uyl-de Groot	01-06-2011
HTA	152002016	The marginal utility of health: direct and indirect valuation of EQ5D differences	Dr. W.H. van den Hout	01-03-2013
HTA	152002017	Confounding in real-life cost-effectiveness studies: assessing the validity and efficiency of different correction techniques	Dr. L.M.A. Goossens	01-07-2011
HTA	152002018	Productivity costs in cost-effectiveness studies on expensive drugs	Dr. L. Hakkaart-van Rooijen	01-04-2010
HTA	152002019	Societal preferences for basic health insurance in the Netherlands	Dr. M.E. van den Akker-van Marle	01-09-2012
HTA	152002020	The Q in the QALY: exploring new methods	Drs. I.H.L. Maes	28-02-2013



Goed Gebruik Geneesmiddelen

HTA	152002021	Acknowledging heterogeneity in Health Technology Assessment to improve efficient use of pharmaceuticals	Dr. J.P.C. Grutters	27-02-2013
HTA	152002022	Estimating indirect medical costs and its associated uncertainty	Dr. P.H.M. van Baal	01-12-2011
HTA	152002023	Significant others in economic evaluations	Dr. H.M. Krol	01-01-2011
HTA	1520020231	Outcomes Beyond the QALY	Dr. H.M. Krol	31-05-2013
HTA	152002024	Quantifying health status in dementia	Dr. P.F.M. Krabbe	28-02-2013
HTA	152002025	Novel modelling approaches to reconcile the paradigms of randomization and representativeness in (cost-) effectiveness analyses: The case of Rheumatoid Arthritis.	Dr. P.M.J. Welsing	01-04-2012
HTA	152002026	Evaluating putative predictive markers in randomized clinical trials of pharmaceuticals	Prof. Dr. P.M.M. Bossuyt	27-11-2012
HTA	152002027	informative censoring in time-to-event data and consequent bias in HTA	Prof. Dr. M.J.C. Eijkemans	01-02-2012
HTA	152002028	Patient preferences for and experiences with chronic medication use: development of two web-based instruments	Dr. E.C.G. van Geffen	01-03-2013
HTA	152002029	Combining N-of-1 trials to estimate population clinical and cost-effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia.	Prof. Dr. B.G.M. van Engelen	01-01-2015
HTA	152002030	From rationing to rationality: an n-of-one trial service for off-label medicines for rare (neuromuscular) diseases	Drs. M.F.Th. Timmen	01-11-2012
HTA	1520020301	Implementatie van n=1-trialmethodologie bij de beoordeling van zorgvergoeding	Dr. S.S. Weinreich	01-07-2015
HTA	152002031	Real options to support decision making on reimbursement of expensive new inpatient drugs	Dr. T.L. Feenstra	01-09-2012
HTA	152002032	Valuation of patient time	Dr. F.R.M. Portrait	06-09-2013
HTA	152002033	Measuring the effects of health interventions on subjective well-being comprehensively: The development and validation of the SWB-xD	Dr. M.C. de Vries	04-03-2014
HTA	152002034	States worse than dead: measurement, estimation, and interpretation	Dr. P.F.M. Stalmeier	04-04-2014
HTA	152002035	Optimal design and analysis for clinical trials in orphan diseases	Dr. I. van der Tweel	31-01-2013
HTA	152002036	Marginal structural models for the analysis of time-dependent drug use in observational studies	Prof. Dr. B.H.C. Stricker	03-07-2014
HTA	152002037	Web-based time trade-off incorporating interviewer help: Efficiency with validity	Dr. W.H. van den Hout	19-12-2014
HTA	152002038	When is it too expensive?	Prof. Dr. W.B.F. Brouwer	01-05-2013
HTA	1520020381	When is it too expensive - VIMP	Prof. Dr. W.B.F. Brouwer	19-04-2016
HTA	152002039	Test of lead time TTO in the general population	Dr. E.A. Stolk	31-05-2013
HTA	152002040	Obtaining causal effect parameters from large databases using physician's preference as instrumental variable	Dr. O.M. Dekkers	21-07-2015
HTA	152002041	Incorporating age-dependent reference points in health technology assessment	Dr. A.E. Attema	28-04-2014



Goed Gebruik Geneesmiddelen

HTA	152002042	What is best when using drugs in chronic disease? A study that uses best-worst scaling to determine patient preferences for the process of drug use in Parkinson Disease.	Dr. J.A. van Til	21-07-2015
HTA	152002043	Establishing reference prices from the national database of the DBC casemix system	Dr. S.S. Tan	21-07-2015
HTA	152002044	A Dutch tariff for the EQ-5D-5L	Dr. E.A. Stolk	28-11-2013
HTA	152002045	HTA guidelines to assist in the decision making process for the reimbursement of orphan drugs	Drs. T.A. Kanters	21-07-2015
HTA	152002046	Integrating evidence on patient preferences in health care policy decisions: are we up for it?	Prof. Dr. C.D. Dirksen	21-07-2015
HTA	152002047	Multiple imputation and bootstrapping in health economic data	Dr. W.H. van den Hout	01-04-2015
HTA	152002048	The risks of conditional reimbursement: stopping can be more difficult than not starting!	Prof. Dr. W.B.F. Brouwer	01-01-2015
HTA	152002049	Are societal perspectives on resource allocation in health care reflected in recommendations and decisions about funding of costly end of life technologies?	Drs. N.J.A. van Exel	01-11-2015
HTA	152002050	Disease models used for decisions on expensive drugs: a new instrument to enable structured model assessment.	Dr. T.L. Feenstra	01-04-2015
HTA	152002051	A roadmap for uncertainty analysis in MCDA	Dr. C.G.M. Groothuis-Oudshoorn	01-01-2016
HTA	152002052	Taming uncertainty: Handling uncertainty in deciding upon new pharmaceuticals	Dr. J.P.C. Grutters	01-11-2015
HTA	152002053	Value judgment of (new) drugs in the Netherlands	Dr. P.F.M. Krabbe	01-10-2015